# DEPARTMENT OF HEALTH AND HUMAN SERVICES

# Centers for Disease Control and Prevention

# Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP): Initial Review

The meeting announced below concerns Occupational Safety and Health Training Project Grants (T03), PAR–10–288, initial review.

In accordance with Section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC) announces the aforementioned meeting:

*Time and Date:* 8 a.m.–5 p.m., November 6, 2013 (Closed).

*Place:* Centers for Disease Control and Prevention, Roybal Campus, Building 19–GCC, 1600 Clifton Road, Atlanta, Georgia 30333, Telephone: (404) 639– 6000.

*Status:* The meeting will be closed to the public in accordance with provisions set forth in Section 552b(c) (4) and (6), Title 5 U.S.C., and the Determination of the Director, Management Analysis and Services Office, CDC, pursuant to Public Law 92–463.

*Matters To Be Discussed:* The meeting will include the initial review, discussion, and evaluation of applications received in response to "Occupational Safety and Health Training Project Grants (T03) PAR–10– 288."

FOR FURTHER INFORMATION CONTACT: Joan F. Karr, Ph.D., Scientific Review Officer, CDC/NIOSH 1600 Clifton Road, Mailstop E–74, Atlanta, Georgia 30333, Telephone: (404) 498–2506.

The Director, Management Analysis and Services Office, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

#### Elaine L. Baker,

Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.

[FR Doc. 2013–24065 Filed 10–1–13; 8:45 am]

BILLING CODE 4163-18-P

# DEPARTMENT OF HEALTH AND HUMAN SERVICES

# Centers for Disease Control and Prevention

#### Advisory Committee on Immunization Practices (ACIP)

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC) announce the following meeting of the aforementioned committee:

Times and Dates:

8:00 a.m.-5:45 p.m., October 23, 2013. 8:00 a.m.-1:00 p.m., October 24, 2013.

*Place:* CDC, Tom Harkin Global

Communications Center, 1600 Clifton Road NE., Building 19, Kent "Oz" Nelson Auditorium, Atlanta, Georgia 30333.

*Status:* Open to the public, limited only by the space available. Meeting is webcast live via the World Wide Web; for instructions and more information on ACIP please visit the ACIP Web site: http://www.cdc.gov/vaccines/ acip/index.html.

Purpose: The committee is charged with advising the Director, CDC, on the appropriate uses of immunizing agents. In addition, under 42 U.S.C. 1396s, the committee is mandated to establish and periodically review and, as appropriate, revise the list of vaccines for administration to vaccine-eligible children through the Vaccines for Children (VFC) program, along with schedules regarding the appropriate periodicity, dosage, and contraindications applicable to the vaccines. Further, under provisions of the Affordable Care Act, at section 2713 of the Public Health Service Act, immunization recommendations of the ACIP that have been adopted by the Director of the Centers for Disease Control and Prevention must be covered by applicable health plans.

Matters To Be Discussed: The agenda will include discussions on: child/adolescent immunization schedule, adult immunization schedule, meningococcal vaccines, pneumococcal conjugate vaccine, herpes zoster vaccine, tetanus, diphtheria and acellular pertussis vaccine, yellow fever vaccine, global immunization update, human papillomavirus vaccines, general recommendations on immunizations, and influenza. Recommendation votes are scheduled for child/adolescent immunization schedule, adult immunization schedule, and meningococcal vaccines. Time will be available for public comment.

Agenda items are subject to change as priorities dictate.

Contact Person For More Information: Felicia Betancourt, National Center for Immunization and Respiratory Diseases, CDC, 1600 Clifton Road NE., MS–A27, Atlanta, Georgia 30333, telephone 404/639– 8836; Email ACIP@CDC.GOV.

The Director, Management Analysis and Services Office, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

#### Elaine L. Baker,

Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.

[FR Doc. 2013–24068 Filed 10–1–13; 8:45 am] BILLING CODE 4160–18–P

# DEPARTMENT OF HEALTH AND HUMAN SERVICES

# Centers for Disease Control and Prevention

# Advisory Committee on Immunization Practices (ACIP)

In accordance with section 10(a) (2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC) announce the following meeting of the aforementioned committee:

*Times and Dates:* 8 a.m.–5:45 p.m., October 23, 2013; 8 a.m.–1 p.m., October 24, 2013.

*Place:* CDC, Tom Harkin Global Communications Center, 1600 Clifton Road NE., Building 19, Kent "Oz" Nelson Auditorium, Atlanta, Georgia 30333.

Status: Open to the public, limited only by the space available. Meeting is Webcast live via the World Wide Web; for instructions and more information on ACIP please visit the ACIP Web site: http://www.cdc.gov/vaccines/ acip/index.html. Purpose: The committee is charged with advising the Director, CDC, on the appropriate uses of immunizing agents. In addition, under 42 U.S.C. 1396s, the committee is mandated to establish and periodically review and, as appropriate, revise the list of vaccines for administration to vaccine-eligible children through the Vaccines for Children (VFC) program, along with schedules regarding the appropriate periodicity, dosage, and contraindications applicable to the vaccines. Further, under provisions of the Affordable Care Act, at section 2713 of the Public Health Service Act, immunization recommendations of the ACIP that have been adopted by the Director of the Centers for Disease Control and Prevention must be covered by applicable health plans.

Matters To Be Discussed: The agenda will include discussions on: child/adolescent immunization schedule, adult immunization schedule, meningococcal vaccines, pneumococcal conjugate vaccine, herpes zoster vaccine, tetanus, diphtheria and acellular pertussis vaccine, yellow fever vaccine, global immunization update, human papillomavirus vaccines, general recommendations on immunizations, and influenza. Recommendation votes are scheduled for child/adolescent immunization schedule, adult immunization schedule, and meningococcal vaccines. Time will be available for public comment. Agenda items are subject to change as priorities dictate.

For Further Information Contact: Felicia Betancourt, National Center for Immunization and Respiratory Diseases, CDC, 1600 Clifton Road NE., MS–A27, Atlanta, Georgia 30333, telephone 404/639– 8836; Email ACIP@CDC.GOV

The Director, Management Analysis and Services Office, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

#### Elaine L. Baker,

Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.

[FR Doc. 2013–24061 Filed 10–1–13; 8:45 am] BILLING CODE 4160–18–P

# DEPARTMENT OF HEALTH AND HUMAN SERVICES

#### Centers for Disease Control and Prevention

## Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP): Initial Review

The meeting announced below concerns Health Promotion and Disease Prevention Research Centers, Funding Opportunity Announcement (FOA) DP14–001, initial review.

In accordance with Section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC) announces the aforementioned meeting:

#### **Times and Dates**

- 8 a.m.–6:30 p.m., November 18, 2013 (Closed)
- 8 a.m.–6:30 p.m., November 19, 2013 (Closed)
- 8 a.m.–6:30 p.m., November 20, 2013 (Closed)
- 8 a.m.–6:30 p.m., November 21, 2013 (Closed)

*Place:* Centers for Disease Control and Prevention, 1600 Clifton Road NE., Global Communications Center, Auditorium B, Atlanta, Georgia 30333.

Status: The meeting will be closed to the public in accordance with provisions set forth in Section 552b(c) (4) and (6), Title 5 U.S.C., and the Determination of the Director, Management Analysis and Services Office, CDC, pursuant to Public Law 92–

463.

*Matters To Be Discussed:* The meeting will include the initial review, discussion, and evaluation of "Health Promotion and Disease Prevention Research Centers, FOA DP14–001".

For Further Information Contact: M. Chris Langub, Ph.D., Scientific Review Officer, CDC, 4770 Buford Highway NE., Mailstop F–80, Atlanta, Georgia 30341, Telephone: (770) 488–3585, Email: *EEO6@cdc.gov.* 

The Director, Management Analysis and Services Office, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

# Elaine L. Baker,

Director, Management Analysis and Services Office, Centers for Disease Control and Prevention. [FR Doc. 2013–24067 Filed 10–1–13; 8:45 am]

BILLING CODE 4163–18–P

#### DEPARTMENT OF HEALTH AND HUMAN SERVICES

#### Centers for Disease Control and Prevention

## Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP): Initial Review

The meeting announced below concerns Health Promotion and Disease Prevention Research Centers, Funding Opportunity Announcement (FOA) DP14–001, initial review.

In accordance with Section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC) announces the aforementioned meeting:

#### **Times And Dates**

8 a.m.–6:30 p.m., November 18, 2013 (Closed); 8 a.m.–6:30 p.m., November 19, 2013 (Closed); 8 a.m.–6:30 p.m., November 20, 2013 (Closed); 8 a.m.– 6:30 p.m., November 21, 2013 (Closed).

*Place:* Centers for Disease Control and Prevention, 1600 Clifton Road NE., Global Communications Center, Auditorium B, Atlanta, Georgia 30333.

*Status:* The meeting will be closed to the public in accordance with provisions set forth in Section 552b(c)(4) and (6), Title 5 U.S.C., and the Determination of the Director, Management Analysis and Services Office, CDC, pursuant to Public Law 92– 463.

*Matters To Be Discussed:* The meeting will include the initial review, discussion, and evaluation of "Health Promotion and Disease Prevention Research Centers, FOA DP14–001".

For Further Information Contact: M. Chris Langub, Ph.D., Scientific Review Officer, CDC, 4770 Buford Highway NE., Mailstop F–80, Atlanta, Georgia 30341, Telephone: (770) 488–3585, Email: *EEO6@cdc.gov.* 

The Director, Management Analysis and Services Office, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

#### Elaine L. Baker,

Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.

[FR Doc. 2013–24062 Filed 10–1–13; 8:45 am] BILLING CODE 4163–18–P

# DEPARTMENT OF HEALTH AND HUMAN SERVICES

## Centers for Disease Control and Prevention

## Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP): Initial Review

The meeting announced below concerns National Center for Construction Safety and Health Research and Translation (U60, Request for Application (RFA) OH13–001, initial review.

In accordance with Section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC) announces the aforementioned meeting:

*Time and Date:* 8 a.m.–5 p.m., November 19, 2013 (Closed); 8 a.m.–5 p.m., November 20, 2013 (Closed); 8 a.m.–12 p.m., November 21, 2013 (Closed).

*Place:* Embassy Suites Alexandria Hotel, 1900 Diagonal Road, Alexandria, Virginia 22314, Telephone: (703)842– 7030.

*Status:* The meeting will be closed to the public in accordance with provisions set forth in Section 552b(c)(4) and (6), Title 5 U.S.C., and the Determination of the Director, Management Analysis and Services Office, CDC, pursuant to Public Law 92– 463.

Matters To Be Discussed: The meeting will include the initial review, discussion, and evaluation of applications received in response to "National Center for Construction Safety and Health Research and Translation (U60), RFA OH13–001."

*For Further Information Contact:* George Bockosh, M.S., Scientific Review Officer, CDC/NIOSH, 626 Cochrans Mill Road, Mailstop P–05, Pittsburgh, Pennsylvania 15236, Telephone: (412)